fbpx

Prepare Now for Medicaid and CHIP Coverage Changes

2023-03-30T08:58:45-04:00March 29th, 2023|

Take steps to keep you and your family insured in case you’re no longer eligible for pandemic-related health care coverage. During the COVID-19 pandemic, people who no longer were eligible for Medicaid or the Children’s Health Insurance Program (CHIP) could keep their coverage. However, continuous CHIP coverage ends in May, and some states will start to disenroll people from Medicaid on April 1.

Apply for new PHA Research Grant

2023-01-05T09:21:06-05:00January 4th, 2023|

The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.

Important Update for the PH Community Regarding CADD Infusion Systems

2022-12-21T13:18:49-05:00December 19th, 2022|

Specialty pharmacies that distribute pulmonary hypertension (PH) medications are currently reaching out to patients and health care professionals to provide an urgent update about specific lots of CADD infusion systems. If you receive a call or email from your specialty pharmacy about this issue, please respond as soon as possible. PHA is actively monitoring this situation and will provide additional information as it becomes available.

PHA Statement on CADD-MS3 and Subcutaneous Treprostinil for Health Care Professionals

2022-12-19T13:59:12-05:00December 9th, 2022|

Since becoming aware of disruptions in CADD-MS3 (MS3) access earlier this year, the Pulmonary Hypertension Association (PHA) has been meeting with stakeholders and advocating on behalf of health care professionals and patients. To date, PHA has met with ICU Medical (device manufacturer); United Therapeutics Corporation (Remodulin); Liquidia (generic treprostinil); and Accredo Specialty Pharmacy. The

PHA Works to Address CADD MS-3 Pump Shortages

2022-12-19T14:58:34-05:00December 5th, 2022|

Since becoming aware of disruptions in CADD-MS3 access earlier this year, the Pulmonary Hypertension Association (PHA) has been advocating for prompt access to treprostinil. Supply chain disruptions have affected supply of the pump’s LCD screen and slowed the manufacturer’s ability to service pumps for reuse. As a result, specialty pharmacies halted new patient starts on the MS3, and eligible patients may have been shifted to a delivery system for Remodulin.

Join the PHPN Mentor Program

2022-08-20T06:20:31-04:00June 1st, 2022|

The Pulmonary Hypertension Association is accepting applications for the 2023 PHPN Symposium Committee, as well as for the position of 2023 PHPN Symposium Vice-Chair. The PHPN Symposium Committee participates in planning the professional education activities for PHA’s biennial PHPN Symposium. Learn more and apply.

Title